BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fretellier N, Idée JM, Guerret S, Hollenbeck C, Hartmann D, González W, Robic C, Port M, Corot C. Clinical, biological, and skin histopathologic effects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis. Invest Radiol 2011;46:85-93. [PMID: 20938344 DOI: 10.1097/RLI.0b013e3181f54044] [Cited by in Crossref: 44] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Kanakia S, Toussaint J, Kukarni P, Lee S, Chowdhury SM, Khan S, Mallipattu SK, Shroyer KR, Moore W, Sitharaman B. Safety and Efficacy of A High Performance Graphene-Based Magnetic Resonance Imaging Contrast Agent for Renal Abnormalities. Graphene Technol 2016;1:17-28. [PMID: 28261636 DOI: 10.1007/s41127-016-0001-2] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Ramalho J, Semelka RC, Ramalho M, Nunes RH, AlObaidy M, Castillo M. Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update. AJNR Am J Neuroradiol 2016;37:1192-8. [PMID: 26659341 DOI: 10.3174/ajnr.A4615] [Cited by in Crossref: 218] [Cited by in F6Publishing: 78] [Article Influence: 31.1] [Reference Citation Analysis]
3 Chopra T, Kandukurti K, Shah S, Ahmed R, Panesar M. Understanding nephrogenic systemic fibrosis. Int J Nephrol. 2012;2012:912189. [PMID: 23193473 DOI: 10.1155/2012/912189] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
4 Wáng YX, Schroeder J, Siegmund H, Idée JM, Fretellier N, Jestin-Mayer G, Factor C, Deng M, Kang W, Morcos SK. Total gadolinium tissue deposition and skin structural findings following the administration of structurally different gadolinium chelates in healthy and ovariectomized female rats. Quant Imaging Med Surg 2015;5:534-45. [PMID: 26435917 DOI: 10.3978/j.issn.2223-4292.2015.05.03] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
5 Bernstein EJ, Isakova T, Sullivan ME, Chibnik LB, Wolf M, Kay J. Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study. Rheumatology (Oxford) 2014;53:1613-7. [PMID: 24706993 DOI: 10.1093/rheumatology/keu151] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
6 Fretellier N, Idée J, Bruneval P, Guerret S, Daubiné F, Jestin G, Factor C, Poveda N, Dencausse A, Massicot F, Laprévote O, Mandet C, Bouzian N, Port M, Corot C. Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide. Br J Pharmacol 2012;165:1151-62. [PMID: 21740412 DOI: 10.1111/j.1476-5381.2011.01585.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
7 Reiter T, Ritter O, Prince MR, Nordbeck P, Wanner C, Nagel E, Bauer WR. Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012;14:31. [PMID: 22607376 DOI: 10.1186/1532-429X-14-31] [Cited by in Crossref: 62] [Cited by in F6Publishing: 25] [Article Influence: 6.2] [Reference Citation Analysis]
8 Pereira LV, Shimizu MH, Rodrigues LP, Leite CC, Andrade L, Seguro AC. N-acetylcysteine protects rats with chronic renal failure from gadolinium-chelate nephrotoxicity. PLoS One 2012;7:e39528. [PMID: 22815709 DOI: 10.1371/journal.pone.0039528] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
9 Swaminathan S, Bose C, Shah SV, Hall KA, Hiatt KM. Gadolinium contrast agent-induced CD163+ ferroportin+ osteogenic cells in nephrogenic systemic fibrosis. Am J Pathol 2013;183:796-807. [PMID: 23867799 DOI: 10.1016/j.ajpath.2013.06.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]